Upload
lythu
View
215
Download
0
Embed Size (px)
Citation preview
Antibiotic Resistancein Belgium :
Current Situation 2005
Marc StruelensService de microbiologie
Hopital Erasme
PEN ERY CLI DOT
GEN KAN SXT CIP
MIN RIF FUC MUP
OXA
The Clinical Challenge ofAntimicrobial Resistance
• Inapropriate antimicrobial therapyincreases the mortality in severe infection
• Infection with antibiotic resistant bacteriaincreases the risk of inappropriate therapy
• Drug spectrum escalation drives excessmedication costs & selective pressure
Impact of antimicrobial treatment appropriateness on patient outcome
(904 cases of microbiologically documented severe sepsis)
0 10 20 300
25
50
75
100Appropriate treatment
Inappropriate treatment
Prob
abili
ty o
f sur
viva
l (%
)
Log-rank test, P < 0.001Adjusted OR = 1.8 (CI95, 1.2-2.6)
Harbarth et al. Am J Med 2003
Microbial etiology and treatment appropriateness in severe sepsis
(904 cases of microbiologically documented severe sepsis)
Inappropriate Antimicrobial
Therapy (n = 211)
Appropriate Antimicrobial
Therapy(n = 693)
- Adequately treated bacteriaStreptococcus pneumoniaeEscherichia coliMethicillin-sensitive S. aureus
- Inadequately treated bacteriaMRSAPseudomonas aeruginosaEnterobacter sppAcinetobacter or Stenotrophomonas
74736
12402428
130176105
8423211
Harbarth et al. Am J Med 2003
The Public Health Challengeof Resistance
• Alert for transmissible resistance– Clonal spread– Gene epidemics
• Early detection enhances efficacy ofinfection control
• Reducing the antibiotic selective pressure by streamlining therapy
MRSA in the UK Press
The Challenging PathogensHealthcare Community
• MDR- Strep. pneumoniae• CA- MRSA• Salmonella (ESBL, FQ)• Campylobacter (FQ,
Macrolides)• Helicobacter pylori• MDR-Tuberculosis
• Staphylococcus aureus(MRSA, GISA, GRSA)
• Enterococci (GRE)• Enterobacteriaceae
(ESBL, carbapenemase, FQ)
• MDR-Pseudomonasaeruginosa
• MDR-Acinetobacterbaumannii
MRSA Proportion in S.aureusBacteremia, EARSS 2003
No data
<1%
1-5%
5-10%
10–25%
25-50%
http://www.earss.nivm.nl.
No data
<1%
1-5%
5-10%
10–25%
25-50%
http://www.earss.nivm.nl.
Trends in MRSA bacteraemia, EARSS, 1999-2004
05
101520253035404550
Neth Den Fin Swe Aus Ger Bel UK Italy Ire
% S
. aur
eus
199920002001200220032004
http://www.earss.rivm.nl
Incidence of Nosocomial MRSABelgium, 1994-2004
3 ,5
3 ,03 ,3
2 ,6
2 ,2
2 ,8
2 ,52 ,6
1 ,8 1 ,8
2 ,42 ,2
1 ,9
2 ,5 2 ,6
3 ,23 ,1
3 ,5
3 ,2
3 ,5
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
4,0
Périodes de surveillance
Inci
denc
e m
oyen
ne g
loba
le/1
000
adm
issi
ons
Jans ISP NSIH MRSA Report 2004
Decrease in nosocomial vs imported MRSA,
Belgium, 1994-2004
0102030405060708090
100
n-M
RSA
/MR
SA g
loba
l (%
)
94/2
95/2
96/2
97/2
98/2
99/2
00/2
01/2
02/2
03/2
Période de surveillance
MRSA nosocomial (échant. clin)
Evolution of geographic distribution of epidemic MRSA PFGE types A1, A20, B2
1995 2001
Denis AAC 2004;48:3625
1995 2001
•♦
♦
♦
♦
♦
♦
••
•
•
•
♦ ••
•• Type B2, ST45-IV• TypeA1, ST247-I♦ Types A20 et A21, ST8-IV• Type G10, ST5-II♦ Type C3, ST5-IV• Type L1, ST22-IV
•
••
•
•
♦ •
Enright et al. PNAS 2002 99:7687Aires de Sousa et al. JCM 2003:3806Melter et al. JCM 2003:4998Denis et al. AAC 2004:3625
••
•
•
• •
•
•
•
•
••
MRSA Co-resistance to non β-lactamsHospitalised patients, Belgium 1995-2003
0%
10%
20%
30%
40%
1 2 3 4 5 6 7 8 9 10 11
Number of drug resistance
% o
f st
rain
s
1995 2003
MRSA resistance to aminoglycosides, Belgium, 1995-2003
0
25
50
75
100
Genta Tobra Amika
% o
f str
ains
resi
stan
t to
1995199720012003
Denis O. et al. Microb Drug Resist. 2003;9:61Denis O. et al. Antimicrob. Agents Chemother. 2004;48:3625Denis O. et al. 15th ECCMID P1570; Copenhagen, Denmark
Proportion of MRSA strains carrying AME genes
Belgium, National Survey 2001
aac(6’)-aph(2“)
ant(4’)
aph(3’)
2% 4%
35%
0.4%
06%
None53%
0
Denis Antimicrob. Agents Chemother. 2004;48:3625
MLSb constitutive resistance phenotype
PEN ERY CLI DOX
GEN KAN SXT CIP
MIN RIF FUC MUP
OXA
MLSb inducible resistance phenotype
PEN ERY CLI DOX
GENKAN SXT CIP
MIN RIF FUCMUP
OXA
Proportion of MRSA strains withMLS resistance genes, Belgium 2001
ermAermCermA + ermCNone
35
30
34
Denis Antimicrob. Agents Chemother. 2004;48:3625
Macrolide-Lincosamide-StreptograminResistance in MRSA and MSSA isolates
Belgium National Survey, 2003
63
43
0
22
4 00
25
50
75
100
Erythro Clinda Q-D
% o
f str
ains
resi
stan
t to
MRSA (n=512)MSSA (n=102)
70 % inducible MLSb
The Shadow Mutant:Vancomycin Intermediate S.aureus / VISA
Denis JAC 2002;50:383
Electron microscopy X 60.000
VISA strain - P1V44 Vancomycin MIC 8 mg/l
S.aureus ATCC 29213
S.aureus Glycopeptide Resistance• Definitions
– GISA : MIC > 4 µg/m for vancomycin or > 8 µg/ml for teicoplanin– Hetero-GISA : sub-population (10-6) able to grow at ≥ 4 µg/ml
vancomycin or at ≥ 8 µg/ml teicoplanin
• National surveys in Belgium• (Denis Microb Drug Resist. 2003;9:61;Nonhoff CMI 2005;11:214)
– Hetero-VISA : from 1.7H% in 1997 to 0.7% in 2001– Hetero-TISA : 2.7% in 2001– PFGE group A (69%) and group D (31%)
• Local surveys in Belgium– Van Eldere (37th ICAAC 1997) : Outbreak of TISA in ICU– Denis (JAC 2002; 50:755) : First Belgian VISA infection– Pierard (Pathol Biol 2004;52:486): 0.6 % hVISA– Glupczynski (ECCMID 2005 P870): 1.5 % hGISA
Population analysis of MRSA isolates with decreased teicoplanin susceptibility,
Belgium, 2001
0
2
4
6
8
10
0 2 4 6 8 10 12 14 16
Teicoplanin (mg/l)
CFU
/ml (
log)
HIP5827ATCC29213Mu3105124151202209242245254412421469632703
Nonhoff Clin. Microbiol. Infect. 2005
Community-Acquired PVL (+)-MRSA :Furonculosis & Necrotizing Pneumonia
Emergence since 1990s Australia, USA, Asia, Europe
Healthy children & young adultsNew disease
Demographic characteristics of 16 patientswith PVL positive MRSA strains, Belgium
Median age (range) 24 (1-70) yrs
Previous beta-lactam therapy 5Familial transmission 1
SexMale 7Female 9
AcquisitionCommunity 15Hospital 1
Travel abroad (Tunisia, Egypt, Ecuador) 3
Denis ECCMID 2005
Clinical origin of 16 PVL positive MRSA strains from Belgium
Community-acquired infections (n = 15)Skin and soft tissue abscesses 8Furonculosis 3
Wound infection 1Cellulitis with bacteremia 1
Hospital-acquired infection (n = 1)
Post-surgical peritonitis 1
Colonization 2
• CA-MRSA PFGE Group X-ST80-IV
• CA-MRSA PFGE Group J-ST30-IV
• CA-MRSA PFGE Group A-ST8-IV
• CA-MRSA PFGE Group Y-ST88-IV
•
•
•
•
•
•••
•
••••
••
Antimicrobial resistance ofPVL-positive MRSA strains
0
25
50
75
100
Tetra Fusi Kana Erythro
% o
f str
ains
resi
stan
t to
96
9
1
Molecular characteristics ofPVL-positive MRSA strains,
Belgium 2002-04
PFGEGroup
MLST SCCmec agr spa No of strains
t044 8
1
1
3
2
Y ST88 IV 3 t186 1
* 1 repeat deletion from t044 , ** single allele variant of ST80
t131*
t044
t008
t019
X ST80 IV 3
X ST80 IV 3
X ST153** IV 3
A ST8 IV 1
J ST30 IV 3
Epidemiology of ESBL-producingEnterobacteria
• Clonal outbreaksinter-hospital epidemic spread by transfer of colonised
patients (France, USA, Belgium,…)
• Plasmid epidemics
• ESBL-producing strains often co-resistant to fluoroquinolones, SXT and aminoglycosides
lens 18/06/03
Geographic distribution of E. aerogenes isolates(n=260)
BE 1
BE 2
?
TEM-24
TEM-3(de Champs. ICAAC,
SFO,1999)
Enterobacter aerogenesPersistence of multi resistant E. aerogenes in Belgium
• Second multicentric survey403 strains from 87 centres– Proportion of MREA: 60%– Incidence of MREA: 3.2/1000
admissions
• stable proportion of ESBL-producing strains– 61% in 2000, 54% in 2003– Co-resistance CAZ and CIP in
99%
14
45
9185
23
70
99 9992
99
15
0
10
20
30
40
50
60
70
80
90
100
CAZ
CTX
FEPIM
I_MEM AK GM CIP
2000-01 2003
% of susceptible strains
De Gheldre, ECCMID 2004, P1122
Escherichia coliEARSS surveillance in Belgium 2002
48.5
6
13.3
3.1 1.9
0
10
20
30
40
50
60
% Resist
Ampi Genta/Tobra FQ C3 ESBL
% ESBL
• n=1185 from blood or CSF
• Prevalence of ESBL: 1.9%
Hendrickx, ECCMID 2004, P1123
ESBL-producing EnterobacteriaceaeHôpital Erasme-ULB 2000-2004
E. aerogenes29%
E. cloacae23%
C. amalonaticus0%
Autres5%
K. pneumoniae10%
E. coli29%
K. oxytoca3%
M. morganii1%
S. marcescens1%
K. ornithinolitica0%
P. stuartii1%
P. mirabilis1%
C. freundii2%
N= 847 ESBL-producing strains from 725 patients
Rodriguez, ECCMID 2005, P429
ESBL-producing EnterobacteriaceaeHôpital Mont-Godinne-UCL 2003-2004
N=80 isolates (7% Enterobacteriaceae)
E. aerogenes64%
E. coli20%
K. pneumoniae5%
K. oxytoca3%
C. freundii6%
P. mirabilis1% E. cloacae
1%
De Gheldre ECCMID 2005, P432
•Diversity of ESBL types
•Emergence of CTX-M group
ESBL-producing E. cloacae in ICU pts by cloneHôpital Erasme, 2000-03
0
2
4
6
8
10
12
aoûtoctdécfév avriljuinaoûtoctdécfév avriljuinaoûtoctdécfév avriljuinaoûtoct
Type PFGE A Type PFGE K Type PFGE LType PFGE Q Other type
No. patient
G P
2000 2001 2002 2003
3 major clones and 10 sporadic clonesSHV+CTX-M ESBL (80% of ESBL)
Frankard, ECCMID 2004
ESBL-producing EnterobacteriaceaePrevalence by species, Hôpital Erasme-ULB, 2000-2004
0
10
20
30
40
50
60
70
80
2000 2001 2002 2003 2004year
n° o
f iso
late
s
E. aerogenesE. cloacaeE. coliK. pneumoniaeLinéaire (E. coli)
p<0.001
0.92 % 1.25 % 1.85 % 2.34 % 3.40 %
Percentage of ESBL producing E. coli
ESBL gene families by speciesErasme Hospital-ULB 2000-2003
0%10%20%30%40%50%60%70%80%90%
100%
E.aerogenes E. cloacae E. coli K.pneumoniae
TEM SHV CTX-M
TEM+CTX-M TEM+SHV CTX-M+SHV
TEM+SHV+CTX-M
N=201 N=58N=103N=272
Increase of CTX-M enzymes among ESBL producing E.coli
Erasme Hospital – ULB, 2000-04
year
0
10
20
30
40
50
60
70
2000 2001 2002 2003 2004
Num
ber o
f cas
es
CTX-M
TEM
SHV
H. Rodriguez. Eurosurveillance Vol 10 .2005
Community-associated emergence of CTX-M/TEM ESBL-producing E.coli
H. Rodriguez. Eurosurveillance Vol 10 .2005
Nosocomial59%
Community associated
24%
Prior hospitalization
17%
Antibiotic resistance in P.aeruginosa:reduced outer membrane
permeability
Antibiotic resistance in P.aeruginosa:
Active efflux systems
MexB/D/F/Y Inner membrane
Outer membraneOprM/J/N
pump
MexA/C/E/X
porin
bridge Periplasmic space
Belgian national survey 2002:b-lactam resistance in
P.aeruginosaVan Eldere JAC 2003
Drug S I R
Pip-tazo 82,5% 17,5%
Cefta 59,0% 12,5% 28,5%
Cefep 50,5% 20% 29,5%
Mero 81,5% 9% 9,5%
J Clin Microbiol 2005;43:1198
Antibiotic Resistance BelgiumCurrent Situation 2005
• Major challenges:– MRSA, ESBL-Enterobacteriaceae,
P.aeruginosa… & others!
• Blurring frontier between community andhospital reservoirs requires new studies
• Need for consolidation of initiatives by BAPCOC & federal platform for hygiene
• Need for concerted international action